Fig. 3

Chidamide and apatinib act synergistically against the primary CD34⁺ AML cells but spare the normal hematopoietic cells. Twenty primary AML bone marrow samples and 8 normal hematopoietic cells were collected and centrifuged using Lymphoprep. These primary AML cells and hematopoietic cells were separately treated with apatinib and chidamide alone or in combination for 24 h. At the end of the treatment, cells were then sorted using the human CD34 antibody and stained with Annexin V/PI kit followed by flow cytometry analysis. A, C The apoptosis-inducing ability of apatinib and chidamide alone or in combinations in primary CD34⁺ AML cells and normal HSCs. B The representative flow plot of cell apoptosis in the primary CD34⁺ AML cells treated as described in A